256 related articles for article (PubMed ID: 35421909)
1. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
[TBL] [Abstract][Full Text] [Related]
2. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
3. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
[TBL] [Abstract][Full Text] [Related]
4. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
5. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
[TBL] [Abstract][Full Text] [Related]
7. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
Ma Q; Li M; Xu G
Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
9. Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study.
Jiang Z; Cai M; Dong B; Yan Y; Wang Y; Li X; Shao C; Zuo L
BMC Nephrol; 2021 Apr; 22(1):148. PubMed ID: 33888083
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
11. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis.
You L; Ye P; Xiao G; Liang J; Kong Y
Turk J Med Sci; 2021 Dec; 51(6):2870-2880. PubMed ID: 34391323
[TBL] [Abstract][Full Text] [Related]
14. Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis.
Zou PM; Li H; Cai JF; Chen ZJ; Li C; Li XW
Chin Med Sci J; 2018 Mar; 33(1):9-19. PubMed ID: 29620510
[TBL] [Abstract][Full Text] [Related]
15. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
16. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
[No Abstract] [Full Text] [Related]
17. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
18. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
20. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]